| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 14611.8 | 15520.5 | 12958.8 |
| Other income | 458.5 | 578.8 | 612.9 |
| Total income | 15070.3 | 16099.4 | 13571.7 |
| Profit before exceptional items & tax | 3551.3 | 4716.6 | 3616.0 |
| Exceptional items | 0.0 | -489.5 | -361.7 |
| Profit before tax | 3551.3 | 4227.2 | 3254.3 |
| Net profit | 2714.0 | 3368.8 | 2149.9 |
| Operating margin | 23.6% | 26.3% | 24.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +26.20% |
|---|---|
| Net profit, quarter on quarter | -19.40% |
| Revenue, year on year | +12.80% |
BSE results filing, NSE: SUNPHARMA. Figures extracted from the filing.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,852.20
- Market cap
- ₹4,44,405 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 36.7×Sector 50.4×
- Promoter holding
- 54.48%+0.00% QoQ
- FII holding
- 14.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Promoter Reclassification
Sun Pharmaceutical has received shareholder approval to reclassify specific persons from the 'Promoter Group' to the 'Public' category, in compliance with SEBI Listing Regulations.
Sun Pharmaceutical Industries Investor Presentation: Key Takeaways
Sun Pharma reports Q1FY27 data showing diversified revenue of Rs 582 Bn for FY26. Key strategy remains scaling Innovative Medicines (22% of sales) and maintaining India market leadership (8.5% share).
Sun Pharmaceutical Industries Legal & Regulatory
Sun Pharma's subsidiaries signed a settlement agreement resolving antitrust litigation in the U.S. for a confidential amount, without any admission of wrongdoing.
Sun Pharmaceutical Industries Merger & Restructuring Worth ₹9.5 Cr
Sun Pharma incorporates a new treasury subsidiary in GIFT City, Gandhinagar. Initial equity subscription is approximately ₹9.50 Crore for group treasury operations.
- Value
- ₹9.50 Cr
Sun Pharmaceutical Industries Credit Rating
Sun Pharma has been assigned international issuer credit ratings of Baa1 by Moody’s and BBB+ by S&P. These investment-grade ratings reflect the company's strong financial profile.
Sun Pharmaceutical Industries Investor Presentation: Key Takeaways
Sun Pharma reported Q1FY27 revenue growth of 10.1% YoY to INR 151,836 million with an EBITDA margin of 28.9%. Growth was driven by Global Innovative Medicines and India formulations.
- Call
- Guides 9% growth